Alpha Synuclein Aggregation Inhibitors is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Alpha-synuclein aggregation inhibitors represent a promising therapeutic strategy for Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA) - collectively known as synucleinopathies. These compounds target the abnormal aggregation of the alpha-synuclein (α-syn) protein, which forms Lewy bodies and contributes to neuronal dysfunction and death.
The rationale for targeting α-syn aggregation stems from:
- Genetic Evidence: SNCA gene multiplications cause familial PD, and mutations (A53T, A30P, E46K) increase aggregation propensity
- Pathological Evidence: Lewy bodies containing fibrillar α-syn are a hallmark of sporadic PD
- Mechanistic Understanding: Oligomeric and fibrillar forms of α-syn are toxic to dopaminergic neurons
Current therapeutic approaches include:
- Small Molecule Inhibitors: Compounds that prevent nucleation and fibril formation
- Antisense Oligonucleotides: Gene therapy approaches to reduce SNCA expression
- Immunotherapies: Active and passive vaccines targeting α-syn
- Protein Stabilizers: Compounds that maintain native α-syn conformation
Several compounds have advanced to clinical trials, including Anle138b, UBL-0401, and antibody-based immunotherapies.
Alpha-synuclein (α-syn) aggregation inhibitors represent a key therapeutic strategy for Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA). These compounds aim to prevent or reverse the pathological aggregation of α-syn into Lewy bodies and glial cytoplasmic inclusions[1].
In synucleinopathies, α-syn undergoes a toxic gain-of-function transformation:
- Native State: Unfolded monomeric protein at presynaptic terminals
- Misfolding: Conformational change to β-sheet rich structure
- Oligomerization: Formation of toxic soluble oligomers (protofibrils)
- Fibrillization: Assembly into insoluble fibrils (Lewy bodies)
Current therapies target various stages of this aggregation cascade.
Small molecules that bind to α-syn and prevent fibril formation:
- Stabilize monomeric form
- Bind to NACore (residues 61-95) - core aggregation domain
- Prevent β-sheet conformation
- Dissociate existing oligomers
Promote clearance of aggregated α-syn:
Reduce α-syn expression:
- ASO therapy targeting SNCA mRNA
- RNAi approaches
- Gene therapy with miRNA delivery
¶ Clinical Candidates
Inosine elevates urate, an endogenous antioxidant[2].
- Mechanism: Antioxidant, 可能 reduces oxidative stress
- Clinical Trials: SURE-PD3 (Phase 3) in PD
- Results: Did not meet primary endpoint
Nilotinib is a BCR-ABL inhibitor that induces autophagy[3].
- Mechanism: Autophagy enhancement via c-Abl inhibition
- Clinical Trials: Phase 2 in PD (NCT03254988)
- Results: Showed signals of biological activity
GLP-1 receptor agonist with neuroprotective effects[4].
- Mechanism: Anti-inflammatory, promotes autophagy
- Clinical Trials: Phase 3 in PD (NCT04232969)
- Results: Primary endpoint not met, but post-hoc analysis positive
Anle138b is a small molecule aggregation inhibitor[5].
- Mechanism: Direct binding to α-syn, inhibits oligomerization
- Development: Phase 1 completed
- Preclinical: Shows rescue in PD models
SynuClean-D is a small molecule identified through high-throughput screening[6].
- Mechanism: Inhibits α-synuclein fibrillation
- Development: Preclinical
- In vivo: Reduces α-syn toxicity in models
ACI-35 (Affiris) is a liposome-based vaccine targeting phosphorylated α-syn at Ser129[7].
- Target: pSer129 α-syn
- Phase: Phase 1b/2a completed
- Results: Safe and induced antibody response
| Antibody |
Target |
Company |
Phase |
| Prasinezumab (PRX002) |
α-syn oligomers |
Roche/Prothena |
Phase 2 |
| Cinpanemab (BIIB054) |
α-syn fibrils |
Biogen |
Phase 2 (failed) |
| MEDI1341 |
α-syn |
AstraZeneca/Prothena |
Phase 1 |
- AAV2-GDNF: Promotes neurotrophic support
- AAV-α-syn antibody: In vivo antibody production
- AAV-SNCA RNAi: Knockdown of α-syn expression
- α-synuclein in CSF: Total, oligomeric, phosphorylated forms
- α-syn RT-QuIC: Seed amplification assay
- Neurofilament light chain (NfL): Marker of neuronal damage
- DaTscan: Dopamine transporter imaging
Primary targets:
- Prevent dopaminergic neuron loss
- Reduce Lewy body formation
- Modulate neuroinflammation
Focus on:
- Cortical α-syn pathology
- Cognitive fluctuations
- Visual hallucinations
Key considerations:
- Oligodendroglial α-syn pathology
- Autonomic dysfunction
- Rapid progression
- BBB penetration: Critical for small molecule efficacy
- Selectivity: Avoiding off-target effects
- Aggregation state targeting: Oligomers vs. fibrils
- Patient selection: Biomarker-driven enrollment
- Timing: Early intervention before irreversible damage
α-syn aggregation inhibitors may combine with:
- Dopaminergic medications
- Neuroprotective agents
- Anti-inflammatory therapies
- Physical/speech therapy
The study of Alpha Synuclein Aggregation Inhibitors has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Bridi JC, Hirth F. Journal of Parkinson's Disease. 2018;8(2):273-290. PMID:29758942
- Parkinson's Study Group. JAMA Neurology. 2020;77(4):427-438. PMID:31940016
- Pagan F, et al. Movement Disorders. 2019;34(5):671-680. PMID:30811099
- Athauda D, et al. The Lancet. 2017;390(10103):1664-1675. PMID:28736114
- Levin J, et al. Movement Disorders. 2019;34(10):1460-1470. PMID:31486558
- Pujols J, et al. Proceedings of the National Academy of Sciences. 2018;115(41):10481-10486. PMID:30254157
- Volc D, et al. The Lancet Neurology. 2020;19(7):589-599. PMID:32593380